While federal agencies typically move at the pace of molasses going uphill, the FDA is suddenly shifting into hyperdrive with its ambitious AI integration plans. The agency has mandated implementation across all centers by June 30, 2025. No small feat. This aggressive timeline comes after a wildly successful generative AI pilot that turned days of scientific review into mere minutes.

FDA Commissioner Martin A. Makary is all in, calling the shift "transformative." No kidding. The agency that's supposed to be regulating AI is now its biggest fan. Funny how that works. Deputy Director Jinzhong Liu can't stop gushing about the productivity gains. Meanwhile, the newly formed CDER AI Council is scrambling to oversee this AI revolution. The increasing use of AI-powered surveillance raises significant privacy concerns for data handling.

The FDA's now swallowed the AI Kool-Aid whole, with brass tripping over themselves to embrace what they should be regulating.

The tech rollout centers on tools like Elsa, which reviews clinical protocols and prioritizes inspections. Scientists now get AI-generated summaries and data syntheses. Real time-savers. The goal? Slash approval timelines for new therapies. Because who doesn't want medications approved faster?

This pivot represents a major shift in focus. Early 2025 saw the FDA suddenly more interested in adopting AI than regulating it. Draft guidance on AI for regulatory support appeared in January, but the regulatory framework remains... flexible. That's one way to put it.

Not everyone's sleeping soundly about this rapid adoption. Questions linger about oversight, transparency, and whether AI might prioritize speed over safety. There's a fine line between cutting bureaucratic red tape and cutting corners on public health.

The FDA insists AI will merely assist reviewers, not replace them. Human judgment stays in the driver's seat. At least that's the claim. The FDA is in discussions with OpenAI regarding implementation strategies and the specialized cderGPT project. The system will operate on a secure platform integrated with internal data, with plans for continuous expansion after full integration. The agency has appointed Jeremy Walsh as chief AI officer to oversee the entire deployment process.

Bold move or reckless gamble? Time will tell if this AI revolution delivers better, faster healthcare innovations—or just faster approvals with unforeseen consequences. Either way, the FDA's molasses days are clearly over.